Drug
Flibanserin clinical trials
Also written Addyi.
- studies test it
- 16
- open now
- 0
- in phase 3
- 10
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2006 | 4 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 10
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 3
Sprout Pharmaceuticals, Inc (11) · Andrew McDonald (1) · Genuine Research Center, Egypt (1) · Boehringer Ingelheim (1) · Mohit Khera (1) · University of Chicago (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses flibanserin is read from its arms, and is right about nine times in ten.
Testing it · 16
- Flibanserin in Men Receiving Androgen Suppression for Prostate CancerCompletedPhase 2Andrew McDonaldNCT04743934Written as Flibanserin 100 MG
- Hypoactive Sexual Desire Disorder in MalesTerminatedPhase 2Mohit KheraNCT04002661Written as Flibanserin
- Effects of Flibanserin on the Pre- and Post-menopausal Female BrainTerminatedNot applicableUniversity of ChicagoNCT02770768Written as Flibanserin
- Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)CompletedPhase 1Genuine Research Center, EgyptNCT04494191Written as Flibanserin 100Mg Tab
- 12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and DistressTerminatedPhase 3Sprout Pharmaceuticals, IncNCT01040208Written as flibanserin 50 mg to 100 mg qhs
- 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire DisorderCompletedPhase 3Sprout Pharmaceuticals, IncNCT00360529Written as flibanserin
- Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire DisorderCompletedPhase 3Sprout Pharmaceuticals, IncNCT00360555Written as flibanserin
- 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NACompletedPhase 3Sprout Pharmaceuticals, IncNCT00360243Written as flibanserin
- Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North AmericaTerminatedPhase 3Sprout Pharmaceuticals, IncNCT01057901Written as Flibanserin
- A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).TerminatedPhase 3Sprout Pharmaceuticals, IncNCT00441558Written as Flibanserin
- Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal WomenCompletedPhase 3Sprout Pharmaceuticals, IncNCT00996372Written as flibanserin
- Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)CompletedPhase 1Sprout Pharmaceuticals, IncNCT01188603Written as flibanserin 100 mg dose every evening
- Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire DisorderCompletedPhase 3Sprout Pharmaceuticals, IncNCT00996164Written as Flibanserin
- A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire DisorderTerminatedPhase 3Sprout Pharmaceuticals, IncNCT01103362Written as flibanserin
- Flibanserin Randomized Withdrawal Trial in Pre-menopausal WomenCompletedPhase 3Sprout Pharmaceuticals, IncNCT00277914Written as Flibanserin
- to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT01134965Written as Flibanserin plus Digoxin
Given in every arm · 1 — flibanserin is usual care beside what is tested
Codes
What other systems call flibanserin · ClinicalTrials.gg INT003890
- MeSH (NLM) C098107flibanserinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 37JK4STR6ZFLIBANSERINConfirmed FDA, NLM, Wikidata
- RxNorm 1665509Confirmed FDA, Wikidata
- Wikidata Q415996flibanserinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80769FlibanserinOne source FDA
- DrugBank DB04908One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C098107 | flibanserin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 37JK4STR6Z | FLIBANSERIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1665509 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415996 | flibanserin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80769 | Flibanserin | One source FDA |
| DrugBank | DB04908 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.